Shares of RIBOLIFE-B (06938) rose more than 6% during the trading session. At the time of writing, the stock is up 4.69%, trading at HK$50.50 with a turnover of HK$15.096 million.
RIBOLIFE-B issued an announcement stating that the company's board was recently informed by Dr. Gan Liming, an executive director, co-CEO, and global head of R&D, that Dr. Gan has further purchased 6,800 H-shares of the company in the open market using personal funds. Following this purchase, as of July 10, 2026, Dr. Gan has acquired a total of 20,000 H-shares in the open market using personal funds. Dr. Gan expressed full confidence in the overall development prospects and potential growth of the group. Subject to compliance with applicable laws and regulations, Dr. Gan does not rule out the possibility of further increasing shareholdings in the company at an appropriate time.
A research report from China Post Securities points out that RIBOLIFE-B is one of the early global pioneers in the small nucleic acid field and has established an international R&D platform. In terms of overseas business development, following the 2023 collaboration with Boehringer Ingelheim (BI), the company achieved another breakthrough in 2026. It licensed the global rights for six siRNA drugs in the MASH field to Madrigal for a $60 million upfront payment, potential milestones of up to $4.4 billion, and future sales royalties. Furthermore, the collaboration with BI has already achieved three milestones, with the project progressing steadily and generating a continuous cash flow, indicating that the company's siRNA technology platform has gained validation from overseas pharmaceutical companies.
China Post Securities released a research report assigning a "Buy" rating to RIBOLIFE-B (06938). The report notes that the company is still in the investment phase for innovative drug R&D and is one of the earliest global pioneers in the siRNA drug field, with several high-potential drug candidates leading in development progress. The institution forecasts the company's revenue for 2026, 2027, and 2028 to be approximately RMB 300 million, RMB 330 million, and RMB 360 million, respectively, representing year-on-year growth of 100%, 10%, and 10%.
Comments